ABSTRACT
The lack of identified clinical biomarkers in Fragile X Syndrome (FXS), the most common inherited form of intellectual disability, has limited the successful translation of bench-to-bedside therapeutics. While numerous drugs have shown promise in reversing synaptic and behavioral phenotypes in mouse models of FXS, none have demonstrated clinical efficacy in humans. Electroencephalographic (EEG) measures have been identified as candidate biomarkers as EEG recordings of both adults with FXS and mouse models of FXS consistently exhibit increased resting-state gamma power. However, the developmental timing of these EEG differences is not known as thus far EEG studies have not focused on young children with FXS. Further, understanding how EEG differences are associated to core symptoms of FXS is crucial to successful use of EEG as a biomarker, and may improve our understanding of the disorder. Resting-state EEG was collected from FXS boys with full mutation of Fmr1 (32-84 months old, n=11) and compared with both age-matched (n=12) and cognitive-matched (n=12) typically developing boys. Power spectra (including aperiodic and periodic components) were compared using non-parametric cluster-based permutation testing. Associations between 30-50Hz gamma power and cognitive, language, and behavioral measures were evaluated using Pearson correlation and linear regression with age as a covariate. FXS participants showed increased power in the beta/gamma range (∼25-50Hz) across multiple brain regions. Both a reduction in the aperiodic (1/f) slope and increase in beta/gamma periodic activity contributed to the significant increase in high-frequency power. Increased gamma power, driven by the aperiodic component, was associated with better language ability in the FXS group. No association was observed between gamma power and parent report measures of behavioral challenges, sensory hypersensitivities, or adaptive behaviors. The observed positive association between increased aperiodic gamma power and language supports hypotheses that increased E/I ratios observed in FXS mouse models may reflect beneficial compensation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Support for this work was provided by: FRAXA Research Foundation, Autism Science Foundation, Thrasher Research Fund, Society for Developmental Behavioral Pediatrics, The Pierce Family Fragile X Foundation, Harvard Catalyst Medical Research Investigator Training Award, and the National Institutes of Health (1T32MH112510, 1K23DC017983-01A1, and R01DC010290)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board approval was obtained from Boston Children's Hospital (IRB#P00025493, IRB#P00018377) prior to starting the study. Written, informed consent was obtained from all caregivers prior to their children's participation in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interests: The authors declare that they have no conflicts of interest
Funding: Support for this work was provided by: FRAXA Research Foundation, Autism Science Foundation, Thrasher Research Fund, Society for Developmental Behavioral Pediatrics, The Pierce Family Fragile X Foundation, Harvard Catalyst Medical Research Investigator Training Award, and the National Institutes of Health (1T32MH112510, 1K23DC017983-01A1, and R01DC010290)
Data Availability
The data sets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
